Literature DB >> 9846512

Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process?

D R Jeyarajah1, G J Netto, S P Lee, G Testa, O Abbasoglu, B S Husberg, M F Levy, R M Goldstein, T A Gonwa, G W Tillery, J S Crippin, G B Klintmalm.   

Abstract

BACKGROUND: The possibility of primary sclerosing cholangitis (PSC) recurrence after liver transplantation has been debated. The aim of this study is to examine whether recurrent PSC and chronic rejection (CR) are different expressions of the same disease process.
METHODS: One hundred consecutive patients receiving 118 grafts for the diagnosis of PSC were reviewed and placed into three groups: group A, recurrent disease, as evidenced by cholangiographic and pathologic findings with radiographic arterial flow to the liver (n=18; 15.7%); group B, those who developed CR (n=15; 13.0%); and group C, all others (n=82; 71.3%). Cholangiograms and histopathologic specimens were examined in a blinded fashion.
RESULTS: Demographic factors were similar, except for age, with a significantly younger age and more episodes of rejection in groups A and B (P<0.03). Group A had a higher incidence of cytomegalovirus hepatitis (P=0.008). Five-year graft survivals for A, B, and C were 64.6%, 33.3%, and 76.1%, respectively (P=0.0001), 5-year patient survivals were 76.2%, 66.7%, and 89.1%, respectively (P=0.0001), and repeat transplantation rates were 27.8%, 46.7%, and 8.5%, respectively (P=0.005). Radiographically, 90% of cholangiograms in patients with recurrent disease showed at least multiple intrahepatic strictures. Histopathologically, patients with recurrent disease and CR shared many features.
CONCLUSIONS: We have described a high incidence of recurrent PSC and CR in patients who received transplants for PSC. Histopathologic analysis suggests that CR and recurrent PSC could represent a spectrum of indistinguishable disease. However, the distinct difference in clinical outcome, as evidenced by an increased repeat transplantation rate and lower graft and patient survival in the CR group, clearly suggests that they are two distinct entities that require very different treatment strategies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9846512     DOI: 10.1097/00007890-199811270-00006

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  17 in total

1.  Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.

Authors:  A Jain; A J Demetris; R Kashyap; K Blakomer; K Ruppert; A Khan; S Rohal; T E Starzl; J J Fung
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

2.  The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation--a single-centre experience.

Authors:  Karli J Moncrief; Anamaria Savu; Mang M Ma; Vince G Bain; Winnie W Wong; Puneeta Tandon
Journal:  Can J Gastroenterol       Date:  2010-01       Impact factor: 3.522

Review 3.  Recurrence of autoimmune liver diseases after liver transplantation.

Authors:  Nabiha Faisal; Eberhard L Renner
Journal:  World J Hepatol       Date:  2015-12-18

Review 4.  Recurrence and rejection in liver transplantation for primary sclerosing cholangitis.

Authors:  Bjarte Fosby; Tom H Karlsen; Espen Melum
Journal:  World J Gastroenterol       Date:  2012-01-07       Impact factor: 5.742

5.  Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis.

Authors:  Jacqueline B Henson; Yuval A Patel; Julius M Wilder; Jiayin Zheng; Shein-Chung Chow; Lindsay Y King; Andrew J Muir
Journal:  Dig Dis Sci       Date:  2017-04-08       Impact factor: 3.199

Review 6.  Primary sclerosing cholangitis.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

7.  Chronic cholangitis caused by Bordetella hinzii in a liver transplant recipient.

Authors:  Mardjan Arvand; Rita Feldhues; Markus Mieth; Thomas Kraus; Peter Vandamme
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

8.  Comparative analysis of outcomes in living and deceased donor liver transplants for primary sclerosing cholangitis.

Authors:  Randeep Kashyap; Parvez Mantry; Rajeev Sharma; Manoj K Maloo; Saman Safadjou; Yanjie Qi; Ashok Jain; Benedict Maliakkal; Charlotte Ryan; Mark Orloff
Journal:  J Gastrointest Surg       Date:  2009-05-09       Impact factor: 3.452

Review 9.  Post-Transplant Disease Recurrence in Pediatric PSC.

Authors:  Nisreen Soufi; Fateh Bazerbachi; Mark Deneau
Journal:  Curr Gastroenterol Rep       Date:  2018-08-06

10.  Chemokine Receptor-5Delta32 Mutation is No Risk Factor for Ischemic-Type Biliary Lesion in Liver Transplantation.

Authors:  Christoph Heidenhain; Gero Puhl; Christian Moench; Anja Lautem; Peter Neuhaus
Journal:  J Transplant       Date:  2009-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.